The study adds clinical evidence for CompuFlo's safety advantage, which could support gradual adoption in neuromodulation and pain management. However, without revenue data or a near-term catalyst, the stock is likely to trade on broader market sentiment and upcoming quarterly results. Monitor the next 10-Q for any revenue acceleration from increased procedure volumes.
Price Chart
Executive Summary
Milestone Scientific highlighted a new peer-reviewed study in Operative Neurosurgery showing that its CompuFlo Epidural System reduced composite complications by 91% during spinal cord stimulator implantation. The press release is promotional, citing growing clinical adoption but providing no new financial data or regulatory catalysts.
Key Facts
- New study in Operative Neurosurgery from UTMB showed CompuFlo guidance associated with 91% reduction in odds of composite complications (CSF leak, blood patch, radiculopathy) in SCS procedures.
- CompuFlo has been evaluated or utilized across more than 40 universities, academic medical centers, and teaching hospitals worldwide.
- No financial data, revenue figures, earnings, or guidance were provided in the press release.
- The press release is a clinical adoption update, not a regulatory or financial event.
Financial Impact
No financial figures disclosed; clinical validation may support future adoption but near-term revenue impact is unquantifiable.
Risk Factors
- No financial data or guidance provided; the press release is purely promotional.
- Competitive pressure from other epidural access technologies and loss-of-resistance techniques.
- Milestone Scientific has a history of low revenue and cash burn; clinical adoption may not translate to near-term profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301977 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | EFFECT | $0.4100 $0.3671 | ▲ +10.46% | ▲ +12.41% | $0.3100 (+24.39%) |
Sep 18, 2026 5w ago | S-3/A | $0.3908 $0.4100 | ▲ +4.91% | ▲ +5.93% | $0.3100 (−20.68%) |
Aug 14, 2026 10w ago | Press Release | $0.4951 $0.4808 | ▼ −2.89% | ▼ −1.52% | $0.3100 (−37.39%) |
Jul 31, 2026 12w ago | 8-K | $0.3990 $0.4811 | ▲ +20.58% | ▲ +17.07% | $0.3100 (−22.31%) |
Jul 29, 2026 12w ago | 8-K | $0.3911 $0.4650 | ▲ +18.90% | ▲ +15.27% | $0.3100 (−20.74%) |
Jun 10, 2026 19w ago | EFFECT | $0.3899 $0.3400 | ▲ +12.80% | ▲ +16.23% | $0.3100 (+20.49%) |
Jun 2, 2026 20w ago | S-3 | $0.3900 $0.3900 | · 0.00% | ▼ −3.82% | $0.3100 (+20.51%) |
May 27, 2026 21w ago | Press Release | $0.3900 $0.3900 | · 0.00% | ▼ −1.21% | $0.3100 (−20.51%) |
May 14, 2026 23w ago | Press Release | $0.3400 $0.3900 | ▲ +14.71% | ▲ +15.42% | $0.3100 (−8.82%) |
May 6, 2026 24w ago | 8-K | $0.4700 $0.3500 | ▼ −25.53% | ▼ −27.04% | $0.3100 (−34.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers